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National drug strategy  
and coordination
National drug strategy
Launched in 2009, Ireland’s National Drugs Strategy 
(Interim) 2009-16 aims to tackle the harm caused to 
individuals and society by the use of drugs, through a 
concerted focus on the five pillars of supply reduction, 
prevention, treatment, rehabilitation and research. This 
top-level aim is further elaborated through five strategic 
aims, alongside specific objectives and key performance 
indicators for each pillar. The strategy is accompanied by an 
action plan containing 63 actions that specify the agencies 
responsible for implementation. While the National Drugs 
Strategy focuses predominantly on illicit drugs, Action 1 
called for the establishment of a steering group to develop 
a national substance misuse strategy with the aim of 
covering both illicit drugs and alcohol. The steering group’s 
report was launched on 7 February 2012 and measures 
based on it, such as the Public Health (Alcohol) Bill 2015, 
have been developed by the government (Figure 1).
Like other European countries, Ireland evaluates its drug 
policy and strategy through ongoing indicator monitoring 
and specific research projects. Each year, progress reports 
on the implementation of the strategy and the action 
plans are compiled. In 2016, an external assessment 
of the strategy was completed, which considered the 
strategy’s implementation and generated insights for the 
development of the strategy’s successor. Previously, mid-
term and progress reviews of the 2001-08 strategy were 
undertaken. A new drug strategy is under development and 
should be in place by the end of 2017.
National coordination mechanisms
The Oversight Forum on Drugs is tasked with the inter-
ministerial coordination of Ireland’s drug strategy and includes 
representatives from key ministries and sectors involved in 
implementing the strategy. It is chaired by the minister of state 
with specific responsibility for the strategy, who is attached to 
the Ministry of Health. Strategic and operational coordination 
and the strategy’s implementation at the national level are 
undertaken by the Drug Policy and Social Inclusion Unit 
at the Ministry of Health. At a local level, local and regional 
drug and alcohol task forces are responsible for strategic 
and operational coordination in the implementation of the 
strategy. These structures and the minister of state are both 
supported by the Ministry of Health’s National Coordinating 
Committee for Drug and Alcohol Task Forces. The National 
Advisory Committee for Drugs and Alcohol advises the 
government on different drug policy issues.
 The National Drugs Strategy  
 focuses predominantly  
 on illicit drugs; however,  
 Action 1 called for the  
 establishment of a steering  
 group to develop a national  
 substance misuse strategy  
 with the aim of covering  
 both illicit drugs and alcohol 
FIGURE 1
Focus of national drug strategy documents:  
illicit drugs or broader
Illicit drugs focus
Broader focus
Ireland
Illict drugs focus
NB: Year of data 2015. Strategies with broader focus may include,  
for example, licit drugs and other addictions.
About this report
This report presents the top-level overview of the drug 
phenomenon in Ireland, covering drug supply, use 
and public health problems as well as drug policy and 
responses. The statistical data reported relate to 2015 (or 
most recent year) and are provided to the EMCDDA by the 
national focal point, unless stated otherwise.
An interactive version of this publication, containing links to 
online content, is available in PDF, EPUB and HTML format: 
www.emcdda.europa.eu/countries
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Public expenditure
Understanding the costs of drug-related actions is an 
important aspect of drug policy. Some of the funds 
allocated by governments to expenditure on tasks related 
to drugs are identified as such in the budget (‘labelled’). 
Often, however, the majority of drug-related expenditure is 
not identified (‘unlabelled’) and must be estimated using 
modelling approaches.
The need for drug-related public budgets has been 
mentioned in drug policy documents since the early 
2000s. Estimates of executed expenditures in Ireland are 
available from 2005. The priorities for drug-related public 
expenditure are set out in the National Drugs Strategy. 
The methods and the completeness of the expenditure 
estimates have varied over time. Recently, the method to 
estimate drug-related public expenditure has been defined 
and it has become possible to compare levels of drug-
related public expenditure over time.
In 2015, total drug-related expenditure represented 0.09 % 
of gross domestic product or approximately EUR 237 000 
(Figure 2).
In 2015, the planned budget allocated approximately 52 % 
of spending to health, 27 % to public order and safety, 9 % 
to recreation, culture and religion, 7 % to education and 7 % 
to social protection initiatives.
Between 2009 and 2014, drug-related expenditure in 
Ireland declined by 16 %. However, in 2015, expenditure 
stayed at the same level as in the previous year and 
a 5 % increase was foreseen in the 2016 drug-related 
government budget.
  
FIGURE 2
Public expenditure related to illicit drugs in Ireland
Supply reduction, 27 %
Demand reduction, 73 %
Drug-related
public expenditure
is around
0.09 %
of Ireland’s
GDP 
NB: Based on estimates of Ireland’s labelled and unlabelled public 
expenditure in 2015.
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Drug laws and drug law offences
National drug laws
Possession of any controlled substance without due 
authorisation is an offence under the Misuse of Drugs Acts 
1977 and 1984. The drugs to which the Acts apply are listed 
in their schedules, together with some generic definitions of 
substance groups. The legislation makes a distinction between 
possession for personal use and possession for sale or supply.
Penalties for possession for personal use depend on the 
type of drug (cannabis or other drugs) and on the penal 
proceedings, that is, whether a summary conviction or a 
conviction on indictment is sought. Possession of cannabis 
or cannabis resin for personal use is punishable by a fine on 
first or second conviction; however, third and subsequent 
offences are punishable by up to one year in prison for a 
summary conviction and up to three years for conviction 
on indictment (Figure 3). Possession in any other case is 
punishable by up to one year in prison and/or a fine on 
summary conviction and up to seven years’ imprisonment 
for conviction on indictment. However, the Criminal Justice 
(Community Service) Act 2011 requires courts to consider 
imposing a community service order instead of a prison 
sentence in all cases where up to 12 months’ imprisonment 
might have been deemed appropriate. A Drug Treatment 
Court (DTC), which is based in Dublin, has been running 
since 2001 and was reviewed in 2010 and 2013.
With regard to drug trafficking, different penalties can be 
imposed depending on the circumstances of the offender, the 
type of drug and the quantity involved. Possession for sale or 
supply can attract penalties of up to life imprisonment, with a 
presumptive mandatory minimum sentence of 10 years for the 
possession of drugs with a market value of at least EUR 13 000. 
In 2013, the Law Reform Commission, an independent statutory 
body established by the Law Reform Commission Act 1975, 
recommended repeal of this presumptive sentencing regime.
In response to the new psychoactive substances (NPS), 
which are sold in so-called ‘head shops’, in 2010, more 
than 200 individual substances were controlled under the 
Misuse of Drugs Act 1977; the Criminal Justice (Psychoactive 
Substances) Act 2010 was passed to allow the prohibition of 
supply-related acts involving any harmful NPS.
In 2015, the Court of Appeal effectively annulled earlier 
Declaration Orders banning numerous substances over the 
last two decades, so the Misuse of Drugs (Amendment) Act 
2015 was introduced as emergency legislation to control 
those substances. Further amendments were made in 2016.
  
Drug law offences
Drug law offence (DLO) data are the foundation for 
monitoring drug-related crime and are also a measure of 
law enforcement activity and drug market dynamics; they 
may be used to inform policies on the implementation of 
drug laws and to improve strategies.
The statistical data indicate that the number of DLO incidents 
decreased in Ireland between 2008 and 2013 and has 
remained relatively stable since then. In 2015, the majority 
of DLO incidents were linked to use/possession (Figure 4). 
There has been a decline in recent years in all sub-categories 
of DLO incidents, with the most remarkable reductions in the 
number of DLOs linked to the cultivation or manufacturing 
of drugs and to importation: the figures for 2015 were more 
than 50 % lower than those for 2011. This decline may be the 
result of intensified law enforcement operations and may also 
reflect changing behaviour in drug use. 
FIGURE 3
Legal penalties: the possibility of incarceration for 
possession of drugs for personal use (minor offence)
Ireland
Not for minor cannabis 
possession, but possible 
for other drug possession
For any minor 
drug possession
Not for minor cannabis 
possession, but 
possible for other 
drug possession
Not for minor 
drug possession
FIGURE 4
Reported drug law offences in Ireland 
Use/possession, 75 %
Supply, 25 %
15 119
Drug law oences
NB: Year of data 2015. Other DLOs: 223 offences for driving under  
the influence of drugs and 494 other drug offences including forged  
or altered prescription offences and obstruction under the Drugs Act.
NB: Year of data 2015.
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Drug use
Prevalence and trends
Available data suggest that drug use has become more 
common among the adult general population aged  
15-64 years in Ireland over recent years. Fewer than 
2 in 10 adults reported use of any illicit drug during 
their lifetime in 2002-03, but this figure increased to 
approximately 3 in 10 in 2014-15. Similarly, last-year 
and last-month prevalence of use of any illicit drug has 
increased since the 2011 survey. The most recent survey 
in 2014-15 confirms that cannabis remains the most 
commonly used illicit drug, followed by MDMA/ecstasy 
and cocaine. Illicit drug use is more common among 
males and younger age groups. Among young adults 
(aged 15-34 years), the prevalence of last-year cannabis 
use was stable between the 2006-07 and 2010-11 
surveys but was found to have increased in the most 
recent study.
Reported last-year use of MDMA decreased between 
2006-07 and 2010-11 but increased substantially in 
2014-15; however, cocaine use has remained stable 
(Figure 5).
In 2014-15, the reported prevalence of lifetime NPS use 
among the adult general population aged 15-64 years was 
approximately 4 %. In contrast to trends observed for other 
illicit substances, data from the 2014-15 study demonstrate 
that the prevalence of NPS use in the Irish general 
population has decreased since the 2010-11 survey. 
Among young adults, last-year prevalence decreased from 
6.7 % in 2010-11 to 1.6 % in 2014-15.
NB: Estimated last-year prevalence of drug use in 2015.
FIGURE 5
Estimates of last-year drug use among young adults (15-34 years) in Ireland
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Data on drug use among 15- to 16-year-old students are 
reported from the 2015 European School Survey Project 
on Alcohol and Other Drugs (ESPAD). This study has been 
conducted regularly in Ireland since 1999.
For three of the eight key variables studied, Irish students 
reported prevalence rates that were slightly above the 
ESPAD average (35 countries). This was true for lifetime 
use of cannabis, lifetime use of inhalants and lifetime use 
of NPS, although the differences were not substantial. 
Levels of non-prescribed use of tranquillisers or sedatives 
were below average, while levels of lifetime use of illicit 
drugs other than cannabis were similar to the overall 
average. The trend indicates a decrease in lifetime 
prevalence rates of cannabis between the 2003 and 2007 
surveys, with a stabilisation in prevalence rates between 
2011 and 2015 (Figure 6).
High-risk drug use and trends 
Studies reporting estimates of high-risk drug use can help 
to identify the extent of the more entrenched drug use 
problems, while data on first-time entrants to specialised 
drug treatment centres, when considered alongside other 
indicators, can inform understanding on the nature and 
trends in high-risk drug use (Figure 8).
The latest estimate of high-risk opioid use is from a 2006 
study, which was based on the three-source capture-
recapture method. This study estimated that there were 
approximately 20 790 opioid users (range 18 136-23 576) in 
Ireland and that two thirds of them lived in Dublin (Figure 7).
 A 2006 study estimated  
 that there were 20 790  
 opioid users (range:  
 18 136-23 576) in Ireland  
 and that two thirds of them  
 lived in Dublin 
FIGURE 6
Substance use among 15- to 16- year-old school students in Ireland
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Data from the specialised drug treatment centres indicate 
that opioids (mainly heroin) remain the most common 
primary drug among those entering treatment. Between 
2006 and 2010, heroin was the main problem drug 
reported by new entrants, but this was superseded by 
cannabis in 2011, and this is still the case. Cocaine use 
peaked among new entrants in 2009. Both amphetamines 
and MDMA are reported only very rarely by new entrants to 
treatment. Approximately one quarter of clients entering 
treatment are female; however, this proportion varies 
depending on primary drug and treatment programme. 
For example, females are more likely to seek treatment 
for primary amphetamine or heroin use than for use of 
cannabis or cocaine (Figure 8).
FIGURE 8
Characteristics and trends of drug users entering specialised drug treatment centres in Ireland 
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FIGURE 7
National estimates of last year prevalence of high-risk 
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Drug harms 
Drug-related infectious diseases
Notification data from the Health Protection Surveillance 
Centre (HPSC) indicate that, in 2015, the number of 
new HIV cases and the number of HIV cases in people 
who inject drugs (PWID) had increased since 2014. A 
total of 491 people were newly diagnosed with human 
immunodeficiency virus (HIV); 50 cases were linked to 
injecting drug use (Figure 9). The reasons for this increase 
are under investigation; however, it may be partly explained 
by changes in reporting procedures in some areas of Ireland 
and by the HIV outbreak in Dublin among PWID in 2014/15.
In 2015, approximately half of hepatitis C virus (HCV) cases 
with a known risk factor could be attributed to injecting 
drug use; however, a main risk factor was reported for fewer 
than half of all cases of HCV infection. Old age, high-risk 
injecting practices and increased time spent in prison have 
been associated with HCV-positive status among PWID in 
Ireland. With regard to hepatitis B virus (HBV), a downward 
trend in the number of notifications was observed between 
2008 and 2014; however, an increase was reported in 2015 
and this is likely to be linked to immigration. For more than 
half of the notifications, the transmission route remains 
unknown, although it is thought that sexual transmission is 
the predominant mode of transmission of HBV.
Drug-related emergencies
Of the 4 256 overdose discharges recorded in hospitals in 
Ireland in 2014, approximately 16 % involved narcotic or 
hallucinogenic drugs. In the majority of these cases (524), 
opiates had been used, followed by cocaine (103 cases) 
and cannabis (57 cases).
Emergency departments in two Irish hospitals participate 
in the European Drug Emergencies Network (Euro-DEN) 
project, which was established in 2013 to monitor acute 
drug toxicity in sentinel centres across Europe.
FIGURE 9 
Newly diagnosed HIV cases attributed to injecting drug use
Cases 
per million population
< 3
3.1-6
6.1-9
9.1-12
>12
Ireland
10.8
NB: Year of data 2015, or latest available year. 
Source: ECDC.
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Drug-induced deaths and mortality
Drug-induced deaths are deaths directly attributable to the 
use of illicit drugs (i.e. poisonings and overdoses).
In Ireland, the data are collected and reported by the 
National Drug-Related Death Index. In 2014, the number 
of drug-induced deaths fell slightly, to 214, compared with 
223 deaths in 2013. The majority of those who died were 
male and were in their thirties. Opioids were the drugs 
most commonly associated with drug-induced deaths 
(Figure 10). Prescription drugs were commonly implicated 
in polydrug deaths.
In 2014, despite the small decrease overall in drug-induced 
deaths, the number of deaths in which methadone, heroin, 
cocaine or MDMA was implicated rose. This is probably a 
reflection of the increase in polydrug poisonings.
The drug-induced mortality rate among adults (aged 15-
64 years) was 71 deaths per million in 2014 (Figure 11), 
which is more than three times the most recent European 
average of 20.3 deaths per million. 
 
FIGURE 10 
Characteristics of and trends in drug-induced deaths in Ireland
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FIGURE 11 
Drug-induced mortality rates among adults (15-64 years)
< 10
10-40
> 40
No data
Cases per million population
Ireland
71
NB: Year of data 2014. 
NB:  Year of data 2015, or latest available year.
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Prevention
Drug prevention is one of the pillars of Ireland’s National 
Drugs Strategy 2009-16. The strategy set out to develop a 
framework for prevention activity that is structured around 
universal, selective and targeted prevention interventions. 
Young people and their families are the main target 
groups for drug prevention activities. The strategy supports 
improved delivery of the social, personal and health 
education (SPHE) programme in primary and post-primary 
schools and coordinates the activities and funding for 
interventions that target young people in out-of-school 
settings with the aim of optimising their impacts.
Prevention interventions
Prevention interventions encompass a wide range of 
approaches, which are complementary. Environmental 
and universal strategies target entire populations, selective 
prevention targets vulnerable groups that may be at greater 
risk of developing drug use problems, and indicated 
prevention focuses on at-risk individuals.
While environmental prevention interventions are not 
specifically identified in the national strategy, relevant 
activities are focused around increasingly restrictive 
alcohol and tobacco controls at the national level. Local-
level strategies are also being developed, which set out 
to change the environment in which substance use takes 
place, rather than focusing on the ‘problem users’ per 
se. An example of this is a pilot project to implement 
community mobilisation measures to tackle alcohol-related 
harm in high-risk local communities.
Drug prevention interventions in primary and post-primary 
schools are delivered through the SPHE programme. This 
programme is a mandatory part of the school curriculum 
and supports the personal and social development, 
health and well-being of students through 10 modules, 
including a module on substance use. The themes and 
content of modules are built around helping students to 
understand the nature of social influences that impact 
on their development and decision-making, and helping 
them to develop adequate life skills to improve their 
self-esteem, develop resilience and build meaningful and 
trusting relationships. The primary school SPHE substance 
misuse module (‘Walk Tall’) has recently been updated 
and revised. In post-primary schools, the use of harm 
reduction approaches has been approved as part of the 
SPHE programme. From 2017 onwards, SPHE will be 
incorporated into a new compulsory area of learning for 
post-primary school pupils called ‘Wellbeing’.
In the community, prevention programmes are provided in 
various settings, such as youth clubs and youth cafés, and 
by means of diversion activities that are provided by the 
statutory, voluntary and community sectors. This sector has 
been further strengthened by the launch of the National 
Youth Strategy 2015-20, which aims to ensure that young 
people have access to high-quality, effective programmes 
that respond to their needs and are designed to secure 
good outcomes for them.
Selective prevention programmes target at-risk groups and 
sub-groups of the general population, including the children 
of drug users, early school leavers and those involved in 
antisocial behaviour. Selective prevention interventions 
also support the families of drugs users, and community 
development is acknowledged as an important step in 
building the capacity of local communities to avoid, or 
respond to and cope with, drug problems. Interventions 
that aim to address early school leaving include the 
Department of Education and Skills’ main instrument to 
address educational disadvantage, the Delivering Equality 
of Opportunity in Schools (DEIS) programme. This aims 
to improve attendance, participation and retention in 
designated schools located in disadvantaged areas, 
including the Local Drug Task Force (LDTF) areas. The 
School Completion Programme (SCP) targets those most at 
risk of early school leaving as well as those who are already 
outside the formal educational system. The Strengthening 
Families programme is a parenting and family skills initiative 
for high-risk families. It has been implemented in several 
LDTF areas and has been subject to evaluation in the Irish 
context, where it has been found to have positive outcomes 
for participants. The needs of children living with, and 
affected by, parental substance use are the target of the 
National Hidden Harm Project.
Indicated prevention programmes in Ireland target 
children with attention deficit disorders and behavioural 
problems and who abuse illicit and licit substances, as 
well as teenagers from disadvantaged families. Indicated 
prevention programmes tend to be provided as part of 
broader services for vulnerable children and young people. 
For example, the Child and Adolescent Mental Health 
Service teams are the first line of specialist mental health 
services for children and young people.
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Harm reduction
The current Irish national drug strategy aims to reduce 
harm-related to substance use and drug-related infectious 
diseases among PWID through the expansion of needle 
and syringe programmes, including those at community 
pharmacies.
Harm reduction interventions
In Ireland, the provision of needle and syringe programmes is 
a central element of harm reduction service provision. There 
are three models of needle and syringe programmes: fixed-
site facilities, outreach syringe provision and pharmacy-
based programmes.
Harm reduction facilities usually provide a range of sterile 
injecting equipment and materials, including different sizes 
and types of needles and syringes, alcohol swabs and citric 
or acetic acid. Condoms, Stericups or cookers and sterile 
water, non-toxic foil (for smoking heroin), syringe identifiers 
and tourniquets are also available through the needle 
and syringe programmes. In pharmacies, the material 
is distributed in packs containing injecting equipment 
for either three or 10 sterile injections. The pharmacy-
based programme is well accepted and the number of 
pharmacies taking part increased from 42 in 2011 to 115 
by the end of 2014. This type of programme now provides 
the most widespread type of syringe outlet.
FIGURE 12 
Availability of selected harm reduction responses
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czech 
Republic 
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Ireland
Italy
Latvia
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Turkey
United 
Kingdom
Needle and syringe programmes
Take-home naloxone programmes
Drug consumption rooms
Heroin-assisted treatment
NB: Year of data 2016.
Country Drug Report 2017 — Ireland
12
A recent review of Irish needle and syringe programmes, 
published in 2015, identified the need to standardise the 
monitoring of services provided, to increase the uptake 
of testing for blood-borne viral infections and the uptake 
of vaccination, and to provide a wider range of drug use 
paraphernalia to clients. It is estimated that, in 2014, 
specialist syringe programmes served almost 16 000 
individual clients. Pharmacy-based programmes distributed 
236 700 sets of injecting equipment, while the Merchants 
Quay Ireland, a national voluntary agency, provided 
24 266 needle exchanges. In Ireland, the HBV vaccine 
is recommended for several high-risk groups, including 
prisoners and PWID.
In 2015, a two-year naloxone demonstration project was 
initiated in Ireland. The project involved the distribution of a 
pre-filled syringe of naloxone on prescription and training of 
opioid users to administer it. Six general practitioners were 
involved in medical assessments and the prescribing of 
naloxone and approximately 600 people received training. 
Based on the positive evaluation of the project, a roll-out of 
the project has been recommended by the health service 
executive (Figure 12). 
 In 2015, a two-year  
 naloxone demonstration  
 project was initiated  
 in Ireland 
Treatment
The treatment system
The National Drugs Strategy 2009-16 sets out a range of 
priorities, each with associated actions, for drug treatment. 
The overarching categories are the development of general 
drug treatment services; targeting services for specific 
at-risk groups; the development of a quality and standards 
framework; and training and skills development. The 
Health Service Executive (HSE), which manages Ireland’s 
public health sector, is responsible for the provision of all 
publicly funded drug treatment. The management of all 
drug treatment services falls under the remit of the Primary 
Care Division, which oversees a number of national care 
groups. Drug treatment is provided through a network of 
HSE services (public), but also non-statutory/voluntary 
agencies, many of which are funded by the HSE. Some 
private organisations also provide treatment.
The total number of drug treatment services available in 
Ireland showed a strong increase between 1998 and 2004 
and the largest expansion was in the outpatient sector. 
FIGURE 13 
Drug treatment in Ireland: settings and number treated 
Outpatient
Inpatient
Hospital-based residential drug treatment (201)
Other inpatient settings (1 515)
Other outpatient 
settings (270)
Prison (774)
Specialised treatment centres 
(5 554)
Low-threshold
agencies 
(1 175)
NB: Year of data 2015.
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Most drug treatment is provided through publicly funded 
outpatient services. These include 299 specialised drug 
treatment centres, 72 low-threshold agencies and 361 
specialised general practitioners, which provide opioid 
substitution treatment (OST) in the community.
Some outpatient care can be provided through mental 
health services and by private agencies. Inpatient 
treatment is provided through residential centres run by 
voluntary agencies or within psychiatric hospitals. There are 
47 non-statutory agencies that are based on the principles 
of residential care or therapeutic communities and two 
hospital-based detoxification units.
The types of treatment and services offered vary depending 
on the service. Medication-assisted treatment includes 
methadone detoxification, methadone maintenance 
treatment and benzodiazepine detoxification; all of these 
are increasingly provided in outpatient settings. Alternative 
therapies, such as acupuncture, are provided through both 
statutory and community projects. Pregnant opioid users 
are entitled to immediate access to treatment. For drug 
users under the age of 18, special interventions, such as 
psychiatric therapy, family therapy and specially adapted 
medication-free therapy, are provided. OST is provided by 
the specialised HSE outpatient treatment clinics, satellite 
clinics and through specialised general practitioners in the 
community, and in prisons.
The integrated care pathways model was recently piloted in 
Ireland and forms the conceptual basis for the National Drug 
Rehabilitation Framework, which was published in 2010.
Treatment provision
In 2015, approximately 9 500 clients entered drug 
treatment, 4 000 of them for the first time. Most clients 
entered treatment through outpatient settings (Figure 13).
Primary opioid users remain the largest group entering 
treatment in Ireland, they have accounted for a decreasing 
proportion of all treatment entrants over the last few years. 
In contrast, the proportion of primary cannabis clients 
entering the treatment rose between 2007 and 2013. The 
third group of clients are those entering treatment for the 
use of hypnotics and sedatives, mainly benzodiazepines 
(classified as ‘other drugs’) (Figure 14).
On 31 December 2015, 9 917 clients were receiving OST. 
The number of clients receiving OST has increased year on 
year since 2006 (apart from 2011). Although the proportion 
of younger clients has decreased since 2010, the 
proportion of clients aged 45 years or older has increased 
steadily (Figure 15).
FIGURE 14 
Trends in percentage of clients entering specialised drug 
treatment, by primary drug, in Ireland
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FIGURE 15 
Opioid substitution treatment in Ireland: proportions of 
clients in OST by medication and trends of the total 
number of clients
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NB: Year of data 2015. Numbers in treatment on the 31st December.
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Drug use and responses in prison
The Irish Prison Service (IPS), which manages the prison 
system in the country, operates as an executive agency 
under the responsibility of the Ministry of Justice, Equality 
and Defence.
One of the key benchmark criteria relevant to the treatment 
of prisoners is equivalence of care, which entitles prisoners 
to the same care as that available in the community. 
Regular inspections on human rights, living conditions 
and respect of the equivalence of care principle are 
conducted by the office of the Inspector of Prisons, as the 
independent body reporting to the Minister for Justice. 
The IPS and the Probation Service have a multi-agency 
approach to offender and rehabilitation in order to reduce 
offending and improve prisoner outcomes.
The provision of drug-related healthcare is regulated by 
the IPS policy and strategy document ‘Keeping drugs out 
of prisons’, the National Drugs Strategy (interim) 2009-16, 
the IPS three-year strategic plan 2012-15, and the joint IPS-
Probation Service strategic plan 2015-17.
Drug treatment services in prison are sub-contracted to 
drug treatment services based in the community and to 
private consultants, including pharmacists.
Counselling services have been provided by agencies 
providing services to PWID. These services provide 
structured assessments, individual counselling, therapeutic 
group work, harm reduction interventions, multidisciplinary 
care and release planning interventions; they use different 
modalities, including brief interventions, motivational 
interviewing and motivational enhancement therapy, such 
as the 12-step facilitation programme.
Between 2009 and 2015, almost 5 500 prisoners received 
drug treatment, which was mainly for opioid use. The main 
type of treatment was methadone maintenance treatment, 
which was provided through pharmacists. A specific 
programme has also been put in place for prisoners 
to detoxify from methadone and benzodiazepines. 
Vaccination against HBV is recommended for several high-
risk groups, including prisoners. A 2010 study estimated 
that the prevalence of HIV infection among prisoners was 
6 % and the prevalence of HCV infection was 41.5 %.
Despite general improvements in healthcare and drug 
treatment, prison overcrowding in recent years has 
represented an obstacle to the provision of drug-related 
services in Irish prisons.
 Between 2009 and 2015  
 almost 5 500 prisoners  
 received drug treatment,  
 which was mainly for  
 opioid use 
Quality assurance
A number of methodological guidelines and standards 
have been developed to assure the quality of drug demand 
reduction activities in Ireland.
Quality standards with practical information on best 
practice in substance use education in Ireland have been 
published as a manual. This is based on a substantial review 
of international research and provides guidelines for the 
development and enhancement of substance use education 
in school, youth work and community-based settings. In 
2013, guidelines to promote positive mental health among 
school students were launched. The quality of SPHE is 
regularly assessed through school inspections, which involve 
observations of lessons, reviews of lesson materials, self-
evaluations by teachers and surveys among students.
Standards in the overall youth work sector are underpinned 
by the National Quality Standards Framework (NQSF) for 
Youth Work. To support this process, in 2015, three Quality 
Standards Officers from the City of Dublin Education and 
Training Board were co-located to the Department of 
Children and Youth Affairs. Their role is to ensure better 
cohesion between national youth policy and practice. 
There are also government-published quality standards for 
volunteer-led youth groups. The standards are based on 
three core principles: young person centred; the safety and 
well-being of young people; and a focus on developmental 
and educational services for young people.
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In terms of treatment and rehabilitation services, one of the 
priorities set out in the National Drugs Strategy is to develop 
a clinical and organisational governance framework for all 
treatment and rehabilitation services. In order to improve 
the quality of OST, guidelines for prescribing methadone 
in pregnancy were issued in 2013. The clinical guidelines 
for OST were published in 2016 and are the first national 
guidelines applicable in HSE treatment clinics, as well as 
in primary care settings; they update and replace the 2008 
guidelines, (Working with Opiate Users in Community Based 
Primary Care), and provide guidance on the treatment 
of opioid dependence in Ireland. The guidelines target 
clinicians and patients in the management of OST and 
also target the community and voluntary services that are 
supporting treatment and rehabilitation.
 Quality standards  
 provide guidelines for  
 the development and  
 enhancement of substance  
 use, education of substance 
 use, education in school,  
 youth work and  
 community-based settings 
Drug-related research
Research is one of the four pillars of current Ireland’s 
National Drugs Strategy and has two main objectives: 
(i) to make data available on the extent of drug misuse 
among all marginalised groups; and (ii) to gain greater 
understanding of the factors that contribute to the misuse 
of drugs. The areas of prevalence, prevention, treatment 
and the consequences of problem drug use were listed as 
priorities and account for most of the main projects in this 
area. Funding is made available mainly from government 
sources. The Department of Health has the responsibility 
for coordinating the implementation of the National 
Drugs Strategy 2009-16 and funds the National Advisory 
Committee on Drugs and Alcohol to identify priority 
information gaps and deficiencies in the area of drugs and 
to commission research to fill these gaps.
The National Advisory Committee on Drugs and Alcohol 
commissions research, much of which is undertaken by 
university departments.
The national focal point coordinates two main reporting 
systems. The HRB National Drugs Library online repository 
contains more than 12 000 reports, articles, systematic 
reviews and accounts of parliamentary debates and other 
items. The library publishes several factsheets based on 
data collected by the national focal point to the EMCDDA. 
The library also produces a series of rapid reviews in 
consultation with policymakers and stakeholders in the 
community and voluntary sector. In 2016, the library 
facilitated the preparation of a framework that can be 
used by to develop a system of shared measurement 
of common outcomes in rehabilitation and social 
reintegration work.
Drugnet Ireland is the Irish focal point’s quarterly bulletin 
of research, evaluation and surveillance, covering alcohol 
and other drug research, and is available in both electronic 
and hard-copy format. Drugnet Ireland keeps policymakers, 
educators and practitioners abreast of current happenings 
in their area.
 The National Advisory  
 Committee on Drugs and  
 Alcohol commissions  
 research, much of which is  
 undertaken by university  
 departments 
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Drug markets 
In 2014, the first comprehensive study of illicit drug 
markets in Ireland was published by the National Advisory 
Committee on Drugs and Alcohol and the Health Research 
Board. This study examined the nature and organisation of 
Irish drug markets and analysed the different factors that 
influence their development, as well as the impact of law 
enforcement interventions.
Typically, illicit drugs are trafficked into Ireland by sea (in 
freight transported by ferry) or by air through Dublin or Cork 
Airports. A number of products have been intercepted in 
the postal system in controlled deliveries.
Based on police data and information, the cultivation of 
domestic cannabis has recently been increasing. Cannabis 
grow houses are generally operated by foreign national 
organised crime groups, which also employ foreign nationals 
to work as gardeners. Although synthetic drug production is 
generally not carried out in Ireland, evidence of small-scale 
production of synthetic stimulants has been reported.
In addition, Irish organised crime groups are reported 
to participate in the tableting of pharmaceutical drugs. 
Benzodiazepines and other ‘Z-drugs’ are reportedly 
obtained in powder form, which is then tableted using 
specialised equipment for a growing market.
Overall, a decline in the number of illicit drug seizures has 
been reported in Ireland since 2007. This mirrors a decrease 
in the number of seizures of cannabis products, which 
remain, however, the most commonly seized type of drug. 
Since 2007, the number of cocaine seizures has decreased 
each year. Similar reductions were evident for heroin 
seizures, except for two periods, between 2011 and 2012, 
when there was a slight increase in the number of seizures 
and between 2013 and 2014, when there was also an 
increase reported. Seizures of MDMA-type substances also 
decreased considerably between 2008 and 2010, followed 
by a period of increase between 2011 and 2014 and a 
reduction in the number of seizures in 2015 (Figure 16). In 
recent years, the number of seizures of NPS has increased.
Ireland reports average prices for the main illicit drugs. The 
mean price of cannabis resin in 2015 was 6 Euro/g, herbal 
cannabis 20 Euro/g, amphetamine 15 Euro/g, cocaine 70 
Euro/g and heroin 140 Euro/g.
Ranges of price and potency/purity data of illicit 
substances seized are shown in Figure 17.FIGURE 16
Drug seizures in Ireland: trends in number of seizures 
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FIGURE 17 
Price and potency/purity ranges of illicit drugs reported in Ireland 
Potency (% THC) Potency (% THC)
Price (EUR/g)
Purity (%)
Price (EUR/g)
Purity (%)
Price (EUR/g)
Purity (%)
Price (EUR/g)
Purity (mg/tablet)
Price (EUR/tablet)
Cannabis resin
0 % EU 87 % EU 0 % EU 46 % EU 
EUR 0 EU EUR 31 EU 
0 % EU 100 % EU 
EUR 10 EU EUR 248 EU 
< 1 % 91 % 
0 mg EU 293 mg EU
EUR < 1 EU EUR 60 EU 
EUR 10 EUR 60
Price (EUR/g)
EUR 0 EU 47 EU 
0 % EU 96 % EU 
EUR 3 EU EUR 214 EU 
3 % 71 % 
0 % EU 100 % EU 
EUR 1 EU EUR 140 EU 
1 % 49 % 
No data
No data No data
No dataNo data
No data No data
No data
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Cocaine 0
  0
NB: Price and potency/purity ranges: EU and national mean values: minimum and maximum.  
Year of data 2015
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   EU range
 Year Country data Minimum Maximum
Cannabis     
Lifetime prevalence of use — schools (% , Source: ESPAD) 2015 18.9 6.5 36.8
Last year prevalence of use — young adults (%) 2015 13.8 0.4 22.1
Last year prevalence of drug use — all adults (%) 2015 7.7 0.3 11.1
All treatment entrants (%) 2015 28 3 71
First-time treatment entrants (%) 2015 45 8 79
Quantity of herbal cannabis seized (kg) No data No data 4 45 816
Number of herbal cannabis seizures 2015 1 049  106 156 984
Quantity of cannabis resin seized (kg) No data No data 1 380 361
Number of cannabis resin seizures 2015  192  14 164 760
Potency — herbal (% THC)  
(minimum and maximum values registered)
No data No data 0 46
Potency — resin (% THC)   
(minimum and maximum values registered)
No data No data 0 87.4
Price per gram — herbal (EUR)   
(minimum and maximum values registered)
No data No data 0.6 31.1
Price per gram — resin (EUR)   
(minimum and maximum values registered)
No data No data 0.9 46.6
Cocaine     
Lifetime prevalence of use — schools (% , Source: ESPAD) 2015 2.1 0.9 4.9
Last year prevalence of use — young adults (%) 2015 2.9 0.2 4
Last year prevalence of drug use — all adults (%) 2015 1.5 0.1 2.3
All treatment entrants (%) 2015 10 0 37
First-time treatment entrants (%) 2015 14 0 40
Quantity of cocaine seized (kg) No data No data 2 21 621
Number of cocaine seizures 2015  364  16 38 273
Purity (%) (minimum and maximum values registered) 2015 0.3-91 0 100
Price per gram (EUR) (minimum and maximum values registered) No data No data 10 248.5
Amphetamines     
Lifetime prevalence of use — schools (% , Source: ESPAD) 2015 1.9 0.8 6.5
Last year prevalence of use — young adults (%) 2015 0.6 0.1 3.1
Last year prevalence of drug use — all adults (%) 2015 0.3 0 1.6
All treatment entrants (%) 2015 1 0 70
First-time treatment entrants (%) 2015 1 0 75
Quantity of amphetamine seized (kg) No data No data 0 3 796
Number of amphetamine seizures 2015  63  1 10 388
Purity — amphetamine  (%)  
(minimum and maximum values registered)
2015 0.6-49 0 100
Price per gram — amphetamine (EUR)  
(minimum and maximum values registered)
No data No data 1 139.8
KEY DRUG STATISTICS FOR IRELAND
Most recent estimates and data reported
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   EU range
 Year Country data Minimum Maximum
MDMA     
Lifetime prevalence of use — schools (% , Source: ESPAD) 2015 3.1 0.5 5.2
Last year prevalence of use — young adults (%) 2015 4.4 0.1 6.6
Last year prevalence of drug use — all adults (%) 2015 2.1 0.1 3.4
All treatment entrants (%) 2015 0 0 2
First-time treatment entrants (%) 2015 1 0 2
Quantity of MDMA seized (tablets) No data No data 54 5 673 901
Number of MDMA seizures 2015  204  3 5 012
Purity (mg of MDMA base per unit)  
(minimum and maximum values registered)
No data No data 0 293
Price per tablet (EUR) (minimum and maximum values registered) 2015 10-60 0.5 60
Opioids     
High-risk opioid use (rate/1 000) No data No data 0.3 8.1
All treatment entrants (%) 2015 48 4 93
First-time treatment entrants (%) 2015 26 2 87
Quantity of heroin seized (kg) No data No data 0 8 294
Number of heroin seizures 2015  758  2 12 271
Purity — heroin (%)  
(minimum and maximum values registered)
2015 3-71 0 96
Price per gram — heroin 
 (EUR) (minimum and maximum values registered)
No data No data 3.1 214
Drug-related infectious diseases/injecting/deaths     
Newly diagnosed HIV cases related to injecting drug use  
(cases/million population, Source: ECDC)
2015 10.8 0 44
HIV prevalence among PWID* (%) 2010 6 0 30.9
HCV prevalence among PWID* (%) 2010 41.5 15.7 83.5
Injecting drug use (cases rate/1 000 population) No data No data 0.2 9.2
Drug-induced deaths — all adults (cases/million population) 2014 71 1.6 102.7
Health and social responses     
Syringes distributed through specialised programmes Not 
available
Not 
available
164 12 314 781
Clients in substitution treatment 2015 9 917  252 168 840
Treatment demand     
All clients 2015 9 489  282 124 234
First-time clients 2015 3 742  24 40 390
Drug law offences     
Number of reports of offences 2015 15 119  472 411 157
Offences for use/possession 2015 10 972  359 390 843
* PWID —  People who inject drugs.     
NB: 24 266 syringes were distributed in 2014 by the Merchants Quay Ireland.
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About the EMCDDA
About our partner in Ireland
The Irish national focal point is located in the Health Research Board 
(HRB). The HRB is a statutory body with a mission to improve health 
through research and information. The HRB is responsible for promoting, 
commissioning and conducting medical, epidemiological and health 
services research in Ireland. Within the HRB, a multidisciplinary team of 
researchers and information specialists work to provide objective, reliable 
and comparable information on the drug situation and its consequences 
and responses in Ireland. The HRB disseminates research findings, 
information and news in the drugs area through its Trends series, through 
the HRB National Drugs Library and through a quarterly research and policy 
bulletin, Drugnet Ireland. Through its research and dissemination activities, 
the HRB aims to inform policy and practice in relation to drug misuse.
Health Research Board 
Grattan House, 67-72 Lower Mount Street
Dublin 2
Ireland
Tel. +353 12345168
Head of national focal point: Mr Brian Galvin — 
bgalvin@hrb.ie
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